Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 3 1

Status

Active not recruiting 26Recruiting 19Completed 15Terminated 11Unknown 5Not yet recruiting 4Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 103Bevacizumab 98Oxaliplatin 97Capecitabine 97Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 82pembrolizumab 77Specimen Handling 77toripalimab 69Injections 63Fluorouracil 62Magnetic Resonance Spectroscopy 61sintilimab 57anlotinib 53130-nm albumin-bound paclitaxel 51Surgical Procedures, Operative 50Docetaxel 49fludarabine 46Pemetrexed 45venetoclax 42Standard of Care 42Leucovorin 42Irinotecan 41lenvatinib 40Biopsy 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × isatuximab × Clear all
NCT07624513 2026-06-03

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer Institute

Phase 3 Not yet recruiting
720 enrolled
Plasma cell

Multiple Myeloma

NCT07601100 2026-06-01

IsaIberVD

Dana-Farber Cancer Institute

Phase 1/2 Not yet recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07334535 2026-01-13

Isa-VRD in TIE HRMM

Peking Union Medical College Hospital

Phase 4 Not yet recruiting
117 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡